During metastasis cancer cells are exposed to potentially destructive hemodynamic forces including fluid shear stress (FSS) while en route to distant sites. However, prior work indicates that cancer cells are more resistant to brief pulses of high-level fluid shear stress (FSS) in vitro relative to non-transformed epithelial cells. Herein we identify a mechanism of FSS resistance in cancer cells, and extend these findings to mouse models of circulating tumor cells (CTCs). We show that cancer cells acutely isolated from primary tumors are resistant to FSS.
INTRODUCTION
Circulating tumor cells (CTCs) are a blood-borne intermediate in the metastatic cascade necessary for colonizing distant organ sites. Tumors may generate millions of CTCs per day, but seminal work in cancer biology has established the concept of "metastatic inefficiency" whereby only a small fraction of these CTCs go on to generate clinically observable metastases [1] [2] [3] . CTCs exist in a fluid microenvironment quite distinct from that of the solid tumor; in the circulation, these cells are exposed to various biological and mechanical stresses that may lead to their demise, including detachment from extracellular matrix, removal from the trophic factors within the primary tumor, newfound contact with the immune system, and exposure to hemodynamic forces 4, 5 . Hemodynamic stresses include fluid shear stress (FSS), shear and compressive stresses due to deformation in the microcirculation and, under some circumstances, traction stresses generated by adherence to the endothelium 6 . Circulatory FSS ranges across 4-orders of magnitude, from less than 1 dyn/cm 2 in lymphatic vessels and the microcirculation to over 1000 dyn/cm 2 in turbulent flows in the heart and in certain pathological settings [7] [8] [9] [10] . Because cancer cells derived from solid tissues appear to lack adaptations in membrane and cytoskeletal features that allow blood cells to withstand hemodynamic forces 11 , it has often been suggested that CTCs are mechanically fragile relative to blood cells . Indeed, a number of studies indicate that many CTCs are dead or dying [12] [13] [14] [15] . However, it is not clear whether death of CTCs is a consequence of the biological and mechanical stresses outlined above or the methods by which CTCs are isolated. It is also possible that many CTCs arrive in the circulation as dead or dying cells, having been passively shed from tumors 15 . Thus, whether viable CTCs are mechanically fragile is still a matter of speculation.
Other experimental evidence suggests that CTCs may be mechanically robust. For example, studies in mouse models indicate that cancer cells injected into various vascular compartments survive their initial exposure to the circulation, with 85-98% of injected cells viable and arrested in the microcirculation within minutes following injection 2, [16] [17] [18] [19] . Association of CTCs with blood components such as platelets or CTC clusters may, in principle, afford mechanical protection to CTCs, but there is little direct evidence to support this 20 . Cell intrinsic mechanisms may also contribute to CTC survival in response to mechanical challenges.
For example, the mechanosensitive pannexin-1 channel mediates survival in response to cell deformation in the microvasculature 21 . Moreover, we found that, unlike their non-transformed epithelial counterparts, cancer cells are remarkably resistant to brief pulses of high-level FSS 22 , and these findings have since been confirmed and extended by others [23] [24] [25] . These studies define that the FSS resistance phenotype is: 1) Evident in cancer cell lines from diverse histologies; 2)
Conferred by the presence of transforming oncogenes including ras, myc and PI3K; 3) Requires the presence of extracellular calcium; and 4) It involves the actin cytoskeleton and the activity of Rho kinase 22, 25 . More recently, we found that exposure to brief pulses of FSS results in cell stiffening, suggesting that this stress-stiffening response of cells is related to the FSS resistance phenotype 26 . A role for cellular mechanical properties in FSS response is further substantiated by reports that lamin A/C contributes to FSS resistance 23 . These data led the hypothesis that cancer cells may actively resist destruction by hemodynamic forces, via changes in cellular mechanics. However, the details of the mechanism underlying FSS resistance have not been described, and whether this feature is functionally relevant for CTCs has not been determined.
RESULTS

Viable primary tumor cells are resistant to FSS
Prior studies on FSS resistance analyzed established cancer cell lines, many of which are derived from metastatic tumors [22] [23] [24] [25] . To address the possibility that FSS resistance is an artifact of cell culture or the result of metastatic selection, we examined the effects of FSS in tumor cells freshly isolated from a genetically-engineered mouse model of prostate cancer and from human melanoma patient-derived xenografts (PDXs). We exposed the cell suspensions to 10 brief (~1msec) pulses of FSS ( max =6400 dynes/cm 2 ) and assessed FSS resistance after every second pulse, as previously described 22 . Prostate epithelial cells from the tumor-bearing mice displayed greater FSS resistance than those from their wild-type counterparts ( Figure 1A ).
Additionally, we found no difference in FSS resistance between cells isolated from PDX generated from primary and metastatic lesions ( Figure 1B ). These data demonstrate that FSS resistance is a feature of cancer cells within the primary tumor and not the result of selection during tissue culture or metastasis. Moreover, we observed that FSS resistance was elevated in Pten/Trp53 double knockout vs. Pten only knockout mice ( Figure 1A) . Given that Pten/Trp53 knockout prostate tumors are known to be markedly more aggressive than their Pten only knockout counterparts 27, 28 , the observed difference suggests that FSS resistance may influenced by tumor aggressiveness.
Given that a number of studies have shown that many CTCs are dead or in the process of dying, and our observations on FSS resistance indicate that the latter is an active cellular process, we hypothesized that apparent CTC fragility may be consequence of cell death. To test this, we induced apoptosis in PC-3 prostate cancer cells by treating them with staurosporine (4µM, 4 hr; confirmed by Annexin V staining) and evaluated FSS resistance ( Figure S1A ). The staurosporine-treated cells were markedly more sensitive to FSS than their untreated counterparts; most were dead after 2 pulses ( Figure 1C ). We also used ionomycin to induce necrotic-like cell death; we found that after a single pulse of FSS nearly all of the ionomycin treated cells had been destroyed ( Figure S1A&B ). These data reaffirm that FSS resistance is an active cellular process.
Cancer cells are intrinsically resistant to small (<12nm) membrane disruptions induced by FSS
Our previous study had demonstrated that exposure to FSS results in membrane damage, detected as uptake of the membrane impermeant dye propidium iodide (PI), in otherwise viable PC-3 prostate cancer cells 22 . To characterize the plasma membrane damage produced by our FSS protocol further, we exposed PC-3 prostate cancer cells to FSS in the presence of fluorescent dextrans of increasing molecular weight and evaluated cellular uptake and viability by flow cytometry. As the size of the dextran probe increased from 3,000 to 70,000 MW, progressively less was taken up by viable cells (Figure 2A ). After 10 pulses of FSS, less than 5% of cells showed evidence of uptake of 70,000 MW dextran, whereas ~30% had taken up 3,000 MW dextran, consistent with the fraction of viable cells that took up PI (668 MW) ( Figure   2B ). Since the Stokes diameter of 70,000-molecular weight dextran is ~12nm 29 , exposure to FSS in our protocol resulted in relatively small, and reparable holes in the plasma membrane of cancer cells. Thus, the FSS resistance of cancer cells could reflect a greater capacity to repair the plasma membrane in response to damage or, alternatively, a greater intrinsic resistance to membrane damage than that of non-transformed cells.
To distinguish between the roles of repair and intrinsic resistance, we developed a flow cytometry-based assay that measures the fraction of viable cells in which membrane damage is repaired or in which no membrane damage occurs ( Figures 2C and S2A ). Before exposing the cells to FSS, we briefly added PI, and afterwards we added counting beads and the viability dye
Hoechst. Because membrane damage must be repaired rapidly in order to maintain cell viability, cells that repair damage to the plasma membrane will be PI-positive but Hoechst-negative.
Intrinsically resistant cells, i.e., those that do not experience membrane damage, will be negative for both dyes. Utilizing this assay, we tested for the capacity of three pairs of cancer and non-transformed cells to resist and repair FSS-induced plasma membrane damage. In the case of the transformed cell lines, PC-3, MDA-MB-231, and TCCSUP, all exhibit a consistent level of intrinsic resistance (33.4%, 31.8%, and 31.8%, respectively) after 10 pulses of FSS ( Figure 2D ; S2B, D, F, H). This level of intrinsic resistance was substantially elevated over that in non-transformed cells, with all three such cell lines, PrEC LH, MCF-10A, as well as primary urothelial cells, having less than 5% after 10 pulses of FSS ( Figure 2D ; S2C, E, G, H). Of the transformed cells that were evaluated, only PC-3 cells had a significant repair fraction (33.5%).
Both MDA-MB-231 and TCCSUP displayed only minimal evidence of repair (7.5% and 3.0%) ( Figure 2D , S2I). Non-transformed MCF-10A cells showed an appreciable repair fraction during initial pulses that was diminished after 10 pulses, indicating that their susceptibility to damage outweighs their ability to repair damage. Both PrEC-LH and primary urothelial cells exhibited only marginal membrane repair ( Figure 2D ; S2I). These data demonstrate that, although membrane repair may contribute to FSS resistance of some transformed cell lines, cancer cells are consistently distinguished from non-transformed cells by intrinsic resistance to membrane damage.
Resistance to FSS depends on RhoA-myosinII axis
To determine the cause of increased intrinsic resistance to FSS-induced damage in cancer cells, we considered previously published findings suggesting that cell stiffness may contribute to FSS resistance. Those studies demonstrated that: 1) PC-3 cells stiffen in response to FSS 26 , and 2) utilization of F-actin and Rho kinase inhibitors can sensitize cancer cells to FSS 22, 25 .
Based on these findings, we hypothesized that members of the Rho-family GTPases, which regulate actin dynamics and actomyosin contractility, are activated in response to FSS. To test this hypothesis, we utilized RhoA/C and RAC1 GTP pulldown assays. We found that in PC-3 cells both RhoA and RhoC were activated in response to FSS, while active RAC1 levels were similar( Figure 3A -B; S3A-D). We then knocked down RhoA and RhoC in a PC-3 derivative cell line and found that only RhoA knockdown cells had decreased FSS resistance ( Figure S3E ).
Utilizing the RhoA activation assay, we found that FSS exposure activates RhoA in both MDA-MB-231 and TCCSUP cells. This demonstrates that cancer cells from diverse tissues respond to FSS in a similar manner by activating RhoA ( Figure 3A -B). Since RhoA activation typically leads to increased levels of F-actin 30, 31 we assayed for cortical F-actin levels in PC-3 after two pulses of FSS exposure by using imaging flow cytometry. This revealed a robust increase in the formation of cortical F-actin, which is consistent with increased RhoA activity ( Figure 3C ;
To determine whether the RhoA-myosin II axis enables cancer cells to maintain elevated intrinsic FSS resistance, we knocked down RHOA in PC-3 cells using RNA interference and the flow cytometry assay described above ( Figure 2C ). We found that the intrinsic FSS resistance was lower in RHOA knockdown vs. scramble control cells ( Figure 3D ; S5A-C). We then used blebbistatin to inhibit myosin II activity in PC-3, MDA-MB-231 and TCCSUP cells and found that the fraction of intrinsically resistant cells was significantly reduced ( Figure 3E ; S5D-H). After 10 pulses of FSS exposure, the membrane repair fraction was not significantly affected by either genetic perturbation of RHOA or pharmacologic (blebbistatin) inhibition of myosin II ( Figure 3D -E, S5A-E). However, blebbistatin treatment did alter the membrane repair during the course of FSS exposure ( Figure S5E ). We also utilized inhibitors that target Rho kinase and myosin lightchain kinase, and found that these too sensitized PC-3 cells to FSS ( Figure S5F ,G). Importantly, at the exposures used in these studies, none of these pharmacologic agents influenced the viability of cells prior to FSS exposure ( Figure S5H ). This indicates that the effects of these compounds on FSS resistance are due to specific inhibition of this mechanism rather than a secondary consequence of cytotoxicity. Taken together, these studies establish the importance of the RhoA-myosin II axis in intrinsic FSS resistance.
Inhibition of myosin II sensitizes cancer cells to hemodynamic forces
We next sought to determine whether the results above implicating myosin II activity in FSS resistance are relevant to CTCs in vivo. To this end, we adapted a mouse model that had been developed to assess the trapping of viable cells in the lung microvasculature following their injection via the tail vein 32 . PC-3 cells were labeled with distinct viable fluorescent dyes, pretreated with either blebbistatin or DMSO (vehicle control), and mixed with 15m fluorescent microspheres prior to injection. Following injection, the mice were euthanized within 3 min to assess the short-term effects of the circulation on trapping of intact cells in the lung microvasculature ( Figure 4A ). We found that the number of intact PC-3 cells lodged in the lungs was significantly lower in the blebbistatin treated vs. DMSO group (49.71±1.57% vs.
59.01±2.67%) ( Figure 4B -E; Table S1 ). Within this experiment we also swapped the dyes used for each treatment condition and found that the results obtained were independent of the dye label used ( Figure 4F ). This indicated that it was the blebbistatin treatment that led to the reduction in the number of intact cancer cells lodged in the lung microcirculation. We reasoned that this effect could have been due to either destruction of blebbistatin-treated cells en route to the lung or an increase in their capacity to traverse the lung microvasculature. To discriminate between these possibilities, we took advantage of the expression of firefly luciferase in the cells tested; we found that the activity of cell-free luciferase correlated with the reduction in viability of the cells exposed to FSS in vitro ( Figure S6A -C). By measuring the cell-free luciferase detected in the plasma of injected mice, we were able to directly quantify the number of cells destroyed during this brief exposure to the circulation. Destruction was 2-fold higher for the blebbistatintreated samples vs. their DMSO-treated counterparts (6.2±0.6% vs. 3.8±0 .6%) ( Figure 4G ; S6D). Although these differences in cell lodgment and destruction were statistically significant, we note that the magnitude of the change was moderate; this could be a consequence of the very brief (few minutes) period of time during which the cancer cells were exposed to the circulation.
To test whether inhibition of myosin II can affect the survival of CTCs over a longer period of time in a mouse model of metastasis, we employed an orthotopic model of metastatic prostate cancer that we had previously developed 33 . Utilizing this model, we treated tumor bearing mice with a single dose of blebbistatin (2.5 mg/kg) and measured CTC number in cardiac blood 3 hours later ( Figure 5A ). Neither the overall tumor burden nor tumor growth differed between the two groups ( Figure S7A-B ). We observed a dramatic reduction in CTC number in mice treated with blebbistatin vs. the vehicle control ( Figure 5B ; S7C). Importantly, over a range of exposures bracketing the in vivo exposure level, blebbistatin was not directly cytotoxic to the prostate cancer cells, indicating that the effects of blebbistatin on prostate cancer CTCs cannot be accounted for by direct toxicity ( Figure S7D ). Moreover, treatment of non-tumor bearing mice with blebbistatin did not affect the number of CD45 + cells detected in blood ( Figure 5C ), indicating that blebbistatin was not toxic to leukocytes. This suggests that the RhoA-myosin II axis promotes FSS resistance specifically in cancer cells rather than in blood cells more generally. Taken together, our data strongly indicate that targeting of the RhoA-myosin II axis could sensitize CTCs to destruction by hemodynamic forces.
DISCUSSION
Cancer cells rely on the circulatory system to spread beyond the primary tumor and regional lymph nodes. This journey presents a mechanical challenge to those originating in solid organs, in part because FSS in the circulation is orders of magnitude higher than that experienced due to interstitial flow in tissues 34 . Here we show that cancer cells actively resist FSS-induced damage to the plasma membrane via a mechanism involving the RhoA-myosin II axis. Our study challenges the long-held notion that CTCs are inherently fragile. Although, numerous studies have shown that an appreciable fraction of CTCs are dead or in the process of dying CTCs following their isolation [12] [13] [14] [15] , the cause of death of these cells remains unclear, as they are subjected to both biological and mechanical insults 4, 5 . Our data indicate that dead and dying cancer cells are highly susceptible to destruction by FSS, suggesting that biological fragility precedes mechanical fragility. Thus, we conclude that mechanical destruction in the circulation is does not contribute significantly to metastatic inefficiency, supporting a number of previous studies 2, [16] [17] [18] [19] .
Precisely how CTCs experience FSS and other hemodynamic forces in the circulation is not clear 34 . The best available evidence indicates that the periods during which CTCs circulate freely last only a few seconds, and that they are interspersed between much longer periods during which they are trapped in the microcirculation due to size restriction. However, CTCs vary in size, and some may be less prone to lodgment in the microcirculation 35 . It is possible that RhoA-myosin II activation protects CTCs from damage by hemodynamic forces as shown here, but that this activity is modulated dynamically as CTCs traverse the microcirculation, with cells that are less stiff more readily "crawling" through narrow channels 36 . In our studies, the reduced lodgment of blebbistatin-treated cells in the lung microcirculation was not evenly balanced by the observed increase in destruction, suggesting that some of these more compliant blebbistatin-treated cells may have avoided lodgment in the microcirculation.
Passage through the heart may expose CTCs to brief, high-magnitude FSS, most similar to that used our in vitro model. Using this model we showed that intrinsic resistance to plasma membrane damage, as opposed to elevated membrane repair, most consistently distinguished cancer cell lines (bladder, breast and prostate) from their non-transformed epithelial counterparts. In PC-3 prostate cancer cells, we observed that exposure to FSS produced small (<12nm) holes in the plasma membrane. These small holes may be rapidly repaired via tensional forces in the plasma membrane 37 .
We show that FSS resistance is a phenotype in cancer cells isolated directly from primary tumors. It is not an artifact of cell culture, nor the product of metastatic selection. Our previous study indicated that FSS resistance is conferred by various transforming oncogenes, such as ras, PI3K and myc. Although it remains to be determined how these oncogenes accomplish this, plausible mechanisms linking ras and PI3K with RhoA activity have been reported 38, 39 . Our finding that exposure to FSS activates RhoA indicates that the development of resistance to FSS is an adaptive response. Previously, we found that exposure to FSS results in cell stiffening 26 , which likely reflects activation of the RhoA-myosin II axis. We do not yet know exactly what triggers RhoA activation in response to the mechanical stimulus of FSS. Our demonstration that extracellular calcium is essential for FSS resistance in cancer cells 22 suggests that calcium influx, through either small membrane disruptions that we detect or possibly a mechanosensitive ion channel, activates RhoA or triggers myosin II contractility directly. Although we find that the RhoA-myosin II axis is important for FSS resistance, our efforts to genetically or pharmacologically inhibit this pathway did not completely ablate FSS resistance. The fact that withdrawal of extracellular calcium achieves this end suggests that other, as yet unidentified, calcium-dependent processes also influence FSS resistance.
Moreover, cell stiffness is a complex phenotype involving not only cytoskeletal contractility but also the properties of the glycocalyx, composition of the plasma membrane, osmotic state and nuclear structure and stiffness, with the latter having already been implicated in FSS resistance 23, 40 . Thus other mechanisms are likely to modulate FSS resistance in cancer cells.
Finally, our demonstration that a blockade of myosin II activity leads to an increase in the destruction of CTCs has interesting implications. It is notable that a reduction of over an orderof-magnitude was evident within 3 hours of treatment with blebbistatin, and that the number of CD45 + leukocytes was not affected. These outcomes suggest that the myosin II-mediated promotion of FSS resistance is specific for cancer cells. It is not yet clear if FSS resistance represents a new anti-cancer target. Intervening in the steps of metastatic dissemination for therapeutic benefit is regarded as challenging as it may occur before cancer diagnosis 41 .
However, metastatic seeding is likely an ongoing process in cancer patients 42 and during surgical and diagnostic procedures, CTCs may be liberated and could be targeted at that time 43 .
Should the reduction in CTCs be found to translate to reduced metastasis, it is possible that the targeting of mechanisms that lead to FSS resistance will be effective in anti-metastatic therapy.
Although blebbistatin is not a drug candidate in humans, other agents such as Fasudil, a ROCK inhibitor, may be effective in this regard 25 . Moreover, because the activation of RhoA-myosin II has been implicated in other aspects of cellular behavior that could promote metastatic colonization, e.g., extravasation, cell invasion and cell survival 44 , the anti-metastatic benefits of inhibiting this pathway may be pleiotropic. This also raises the interesting possibility that exposure to FSS "primes" cells for subsequent metastatic behavior.
Material and Methods
Cell lines
All cells were transfected with an integrating retrovirus that encodes the firefly luciferase gene using procedures previously described 46 . RhoA knockdown lentivirus and its control were generated by transfecting 293FT cells with VSVG and the PLKO.1 vector, with the latter of containing a short hairpin RNA (shRNA) targeting either RhoA or a non-target sequence (Sigma), using the Polyfect reagent (Qiagen). The cells were selected for antibiotic resistance 2 days after transduction, and knockdown was evaluated by western blot analysis.
Chemical Reagents
Cells were treated with blebbistatin (20M, 3 hr) (Selleckchem, S7099), fasudil (5M, 24 hr) (Selleckchem, S1573), ML7 (20M, 1 hr) (Sigma, I2764), ionomycin (10M, 30 min) (Sigma, I9657), or staurosporine (4M, 4 hr) (Selleckchem, S1421) prior to exposure to fluid shear stress (FSS). For mouse studies, blebbistatin (-) (Selleckchem, S7099) was injected once intravenously, at a dose of 2.5 mg/kg.
Fluid shear stress assay
Cells were suspended in DMEM without FBS at a concentration of 5x10 5 cells/mL and exposed to FSS at a flow rate of 250 L/s in a 30 Ga ½" needle using a 5-mL syringe and a PHD1000 syringe pump (703006). For cells expressing luciferase, viability was determined by bioluminescence imaging 22 . For cells that did not express luciferase, the CellTiter-Blue reagent (Promega) was used. In all cases, viability was determined by normalizing signal to the static control (pulse 0).
Flow cytometry
Data were collected using a Becton Dickinson LSR II flow cytometer and analyzed using the FLOWJO platform (FLOWJO, LLC). 
Evaluation of Intrinsic Resistance and Membrane
Quantification of Cortical F-actin
To measure the density and organization of F-actin after shear stress, we exposed PC3 cells to 2 pulses of FSS. To identify dead and damaged cells, we added propidium iodide (1.75 µg/ml) to the cell suspension before FSS. Immediately following FSS, we fixed cells with 1% paraformaldehyde for 20 min. After washing with PBS, cells were stained with 1: Orthotopic prostate xenograft model: 5x10 4 GS689.Li cells were orthotopically injected into the anterior prostate lobe of [8] [9] [10] [11] [12] [13] week-old NSG mice as described previously 49 . As described above, this cell line was derived from the PC-3 parent line by selection for cells that are highly metastatic in vivo 45 . These cells were engineered to express luciferase and enhanced green fluorescent protein (EGFP), which allows for monitoring tumor burden and the detection of CTCs, respectively. Mice were randomized into two groups with similar tumor burden and injected intravenously with 50 µL of either 2.5 mg/kg (-)-blebbistatin or vehicle (15% DMSO, 85% PEG-400). Blood was collected 3 hr after injection by terminal cardiac puncture, and samples were analyzed by flow cytometry as described below.
Image analysis
Microscopy images were acquired using an Olympus BX61 or a Leica SP8 microscope. For imaging of the lung, a region of interest (ROI) encompassing the entire lung section was selected, and images were collected through 4 fluorescence channels and stitched together using microscope software (LAS X, Leica or cellSens, Olympus). Image analysis was performed using the FIJI software 50 channel. The percentage of intact cells lodged in the microvasculature was determined based on the ratio of cells to microspheres in the lungs at p2 vs p0 (pre-injection control sample).
Bioluminescence imaging
After orthotopic tumors were implanted, their growth was monitored to assess tumor burden by weekly bioluminescence imaging. Imaging entailed intraperitoneal injection of 150 mg/kg of Dluciferin (GoldBio, LUCK), followed 5 min later by the detection of bioluminescence using an AMI X imager (Spectral Instruments Imaging); exposure time was 5 minutes. The AMIView
Imaging Software was used to select an ROI including the whole body for quantification of signal intensity.
Cell-free luciferase assay
Assay validation: To validate that cell-free luciferase measurements correlate with the destruction of cells due to FSS, we compared the calculated percentage of cells destroyed by exposure to FSS with the loss of viability as measured with bioluminescence signal (Fig. S9) . CoA, and 0.3mM ATP, 0.3 mg/mL luciferin) was placed in each well to measure luciferase activity. The fractional cell viability as measured in luciferase assay of cells exposed to FSS was plotted against a standard curve of the cell-free luciferase signal generated from cell-lysate from a known quantity of cells.
Application of cell-free luciferase assay to mouse plasma: A standard curve was generated from data for 5x10 5 
Figure 2: Cancer cells resist FSS-induced nanometer-scale disruption of the plasma membrane.
A) Uptake of dextrans of various size and of propidium iodide (PI) in PC-3 cells exposed to FSS. B) Uptake after 10 pulses of FSS. Uptake of both 40,000 and 70,000 MW dextrans decreased in comparison to that of PI (*p<0.05 and **p<0.01, respectively; 1-way ANOVA with Bonferroni correction), C) Schematic of flow cytometry assay for evaluation of intrinsic resistance and membrane repair after exposure to FSS. Shown is sequence of exposure to PI, FSS, and Hoechst dye, making it possible to identify cells that have intrinsic resistance to membrane damage (PI -Hoechst -) and cells that undergo membrane repair (PI + Hoechst -). D) Effects of 10 FSS pulses on intrinsic resistance and membrane repair in transformed cancer cells (PC-3, blue circle; MDA-MB-231, pink circle; TCCSUP, yellow circle) and non-transformed cells (PrEC-LH, blue square; MCF-10A, pink square; Primary urothelial, yellow square) (***p<0.001, t-test, n=3/cell line). Membrane repair after 10 pulses varied among cell lines and did not differ significantly by transformation status (p>0.05, t-test, n=3/cell line). 
